Press Releases

Leading Medical Experts to Discuss Top-Line Results Showing Significant Glycemic Improvement Using BT-001 SAN FRANCISCO --(BUSINESS WIRE)--Mar. 23, 2022-- Better Therapeutics, Inc . (“Better Therapeutics”, NASDAQ: BTTX), a prescription digital therapeutics company developing nutritional cognitive

Data Demonstrates Clinically Meaningful and Statistically Significant Results, Improving Glycemic Control by Reducing A1c 0.4% Versus the Control Group Receiving Standard of Care SAN FRANCISCO --(BUSINESS WIRE)--Mar. 15, 2022-- Better Therapeutics, Inc. (“Better Therapeutics”, NASDAQ: BTTX), a

Medical experts discuss the potential use of prescription digital therapeutics (PDTs) delivering cognitive behavior therapy to address behavioral root causes of disease The role of data generated through randomized, controlled trials and real-world evidence studies on payer coverage and

Major step forward towards reimbursement for software-based treatments including Better Therapeutics’ BT-001 for the treatment of type 2 diabetes SAN FRANCISCO --(BUSINESS WIRE)--Feb. 28, 2022-- Better Therapeutics, Inc . (“Better Therapeutics”, NASDAQ: BTTX), a prescription digital therapeutics

Open-label, randomized, controlled study will evaluate BT-001, a prescription digital therapeutic (PDT) delivering cognitive behavioral therapy to address behavioral root cause of type 2 diabetes Multi-year study will evaluate effectiveness, durability, healthcare utilization and medication changes

SAN FRANCISCO --(BUSINESS WIRE)--Jan. 20, 2022-- Better Therapeutics, Inc. (“Better Therapeutics”; NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, today announced that Kevin Appelbaum ,

Pivotal trial of BT-001 in type 2 diabetes fully enrolled; interim data analysis determines trial is adequately powered and should continue to completion without changes; primary endpoint readout expected in Q1 2022 Early clinical discovery study in nonalcoholic fatty liver disease (NAFLD) and

SAN FRANCISCO --(BUSINESS WIRE)--Nov. 30, 2021-- Better Therapeutics, Inc. (“Better Therapeutics”; NASDAQ: BTTX), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the appointment of Deepti

Primary endpoint data expected in Q1 2022 SAN FRANCISCO --(BUSINESS WIRE)--Nov. 18, 2021-- Better Therapeutics, Inc . (“Better Therapeutics”; NASDAQ: BTTX), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases,

SAN FRANCISCO --(BUSINESS WIRE)--Nov. 11, 2021-- Better Therapeutics, Inc. (“Better Therapeutics”; NASDAQ: BTTX), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the appointment of Major